

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001556327
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Aceragen, Inc.
SEC File Number 001-31918
Address of Issuer 505 Eagleview Blvd.,
Ste. 212
Exton
PENNSYLVANIA
19341
Phone 484-348-1600
Name of Person for Whose Account the Securities are To Be Sold John Kirby

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc One Post Office Sq 33rd Floor Boston MA 02109	18736	12282.9	8423504	07/25/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	11/30/2018	ESPP purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		31	11/30/2018	cash
common	11/30/2017	ESPP Purchase	Idera pharmaceuticals nka Aceragen	<input type="checkbox"/>		12	11/30/2017	cash
common	11/30/2016	ESPP purchase	Idera pharmaceuticals nka Aceragen	<input type="checkbox"/>		13	11/30/2016	cash
common	08/31/2019	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		112	08/31/2019	cash
Common	08/31/2018	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		18	08/31/2018	cash
common	08/31/2017	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		8	08/31/2017	cash
common	08/31/2016	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		10	08/31/2016	cash
common	05/31/2022	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		108	05/31/2022	cash
common	05/31/2019	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		86	05/31/2019	cash
common	05/31/2018	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		13	05/31/2018	cash
common	05/31/2017	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		8	05/31/2017	cash
common	03/23/2021	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		816	03/23/2021	cash
common	02/28/2022	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		601	02/28/2022	cash
common	02/28/2019	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		53	02/28/2019	cash
common	02/28/2018	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		13	02/28/2018	cash
common	02/28/2017	espp purchase	Idera pharmaceuticals nka Aceragen	<input type="checkbox"/>		8	02/28/2017	cash
common	01/10/2021	espp purchase	Idera Pharmaceuticals nka Aceragen	<input type="checkbox"/>		194	01/10/2021	cash
common	01/06/2023	espp purchase	Idera pharmaceuticals nka Aceragen	<input type="checkbox"/>		8	01/06/2023	cash
common	01/06/2023	espp purchase	Idera Pharmaceuticals nka aceragen	<input type="checkbox"/>		16427	01/06/2023	cash
common	01/03/2021	espp purchase	Idera Pharmaceuticals	<input type="checkbox"/>		100	01/03/2021	cash

common	01/03/2020 espp purchase	nka Aceragen Idera Pharmaceuticals <input type="checkbox"/> nka Aceragen	97	01/03/2020 cash
--------	--------------------------	---	----	-----------------

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John J. Kitby C/O Aceragen, 505 Eagleview Blvd. Ste 212 Exton PA 19341	common	07/24/2023	314	307
John J. Kirby C/O Aceragen 505 Eagleview Blvd Ste 212 Exton PA 19341	common	07/14/2023	300	472

144: Remarks and Signature

Remarks

Date of Notice 07/25/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ UBS Financial Services Inc, as attorney-in-fact for John Kirby

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)